Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA warning on home diagnostic kits

This article was originally published in The Tan Sheet

Executive Summary

Pregnancy Test and Rapid HIV Test Kit marketed by the Canadian firm Globus Media are among the unapproved diagnostic products being sold by the company and should not be purchased, FDA says in a Feb. 7 consumer warning. The other six illegal kits are an HCG urine test and tests for syphilis, cocaine, marijuana, amphetamine and dengue fever. Use of the kits may produce false results that could "lead to significant adverse health consequences" if those who test negative do not seek medical treatment or spread a virus to others, the agency notes. The tests have been marketed nationwide through websites. Anyone who has used one of the kits "should be retested using valid test methods," FDA says...

You may also be interested in...



OraSure Seeks Regulatory Feedback For Marketing Home-Use HIV Test

OraSure Technologies will seek guidance from FDA's Blood Product's Advisory Committee on making its OraQuick Advance oral fluid HIV test available over the counter for use in the home

FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility

The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.

Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line

The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS097845

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel